Literature DB >> 17652215

Intact kinase homology domain of natriuretic peptide receptor-B is essential for skeletal development.

Rumi Hachiya1, Yuko Ohashi, Yasutomi Kamei, Takayoshi Suganami, Hiroshi Mochizuki, Norimasa Mitsui, Masaaki Saitoh, Masako Sakuragi, Gen Nishimura, Hirofumi Ohashi, Tomonobu Hasegawa, Yoshihiro Ogawa.   

Abstract

CONTEXT: Natriuretic peptide receptor-B (NPR-B, GC-B in rodents; gene name NPR2) is a guanylyl cyclase-coupled receptor that mediates the effect of C-type natriuretic peptide. Homozygous mutations in human NPR-B cause acromesomelic dysplasia, type Maroteaux (OMIM 602875), an autosomal recessive skeletal dysplasia. NPR-B has an intracellular kinase homology domain (KHD), which has no kinase activity, and its functional significance in vivo is currently unknown.
OBJECTIVE: We examined the functional significance of a novel NPR-B KHD mutation in humans. PATIENTS AND METHODS: A 28-yr-old Japanese male presented with marked short stature (118.5 cm, -9.3 sd). His limbs showed marked shortening in the middle and distal segments. His parents had relatively short stature with height z-scores of -2.75 and -0.98 (his father and mother, respectively). Direct sequencing of coding region of the NPR2 gene of the family was performed. The mutant receptor activity was investigated by saturation binding assay and cGMP measurement. Additionally, interaction between the mutant and wild type allele was investigated by the titration experiments.
RESULTS: We identified a novel missense mutation L658F in KHD of NPR-B in homozygous and heterozygous states in the patient and his parents, respectively. The mutation conferred normal binding affinity for C-type natriuretic peptide but no discernible ligand-induced cGMP production. Furthermore, L658F mutant impaired wild-type NPR-B-mediated cGMP production in a dose-dependent manner, suggesting that short stature found in L658F heterozygote can be caused by its dominant-negative effect.
CONCLUSIONS: This study provides the first evidence that intact KHD of NPR-B is essential for skeletal development.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17652215     DOI: 10.1210/jc.2007-1101

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  25 in total

1.  Further defining the clinical and molecular spectrum of acromesomelic dysplasia type maroteaux: a Turkish tertiary center experience.

Authors:  Pelin Ozlem Simsek-Kiper; Gizem Urel-Demir; Ekim Z Taskiran; Umut Ece Arslan; Banu Nur; Ercan Mihci; Mithat Haliloglu; Yasemin Alanay; Gulen Eda Utine; Koray Boduroglu
Journal:  J Hum Genet       Date:  2020-12-07       Impact factor: 3.172

2.  Cellular Heterogeneity of the Luteinizing Hormone Receptor and Its Significance for Cyclic GMP Signaling in Mouse Preovulatory Follicles.

Authors:  Valentina Baena; Corie M Owen; Tracy F Uliasz; Katie M Lowther; Siu-Pok Yee; Mark Terasaki; Jeremy R Egbert; Laurinda A Jaffe
Journal:  Endocrinology       Date:  2020-07-01       Impact factor: 4.736

3.  Catalytically Active Guanylyl Cyclase B Requires Endoplasmic Reticulum-mediated Glycosylation, and Mutations That Inhibit This Process Cause Dwarfism.

Authors:  Deborah M Dickey; Aaron B Edmund; Neil M Otto; Thomas S Chaffee; Jerid W Robinson; Lincoln R Potter
Journal:  J Biol Chem       Date:  2016-03-15       Impact factor: 5.157

4.  A human skeletal overgrowth mutation increases maximal velocity and blocks desensitization of guanylyl cyclase-B.

Authors:  Jerid W Robinson; Deborah M Dickey; Kohji Miura; Toshimi Michigami; Keiichi Ozono; Lincoln R Potter
Journal:  Bone       Date:  2013-07-01       Impact factor: 4.398

Review 5.  Molecular therapeutic strategies for FGFR3 gene-related skeletal dysplasia.

Authors:  Jia Chen; Jiaqi Liu; Yangzhong Zhou; Sen Liu; Gang Liu; Yuzhi Zuo; Zhihong Wu; Nan Wu; Guixing Qiu
Journal:  J Mol Med (Berl)       Date:  2017-10-23       Impact factor: 4.599

6.  A novel loss-of-function mutation in Npr2 clarifies primary role in female reproduction and reveals a potential therapy for acromesomelic dysplasia, Maroteaux type.

Authors:  Krista A Geister; Michelle L Brinkmeier; Minnie Hsieh; Susan M Faust; I Jill Karolyi; Joseph E Perosky; Kenneth M Kozloff; Marco Conti; Sally A Camper
Journal:  Hum Mol Genet       Date:  2012-10-12       Impact factor: 6.150

7.  Systemic administration of C-type natriuretic peptide as a novel therapeutic strategy for skeletal dysplasias.

Authors:  Akihiro Yasoda; Hidetomo Kitamura; Toshihito Fujii; Eri Kondo; Naoaki Murao; Masako Miura; Naotetsu Kanamoto; Yasato Komatsu; Hiroshi Arai; Kazuwa Nakao
Journal:  Endocrinology       Date:  2009-03-12       Impact factor: 4.736

8.  Circulating osteocrin stimulates bone growth by limiting C-type natriuretic peptide clearance.

Authors:  Yugo Kanai; Akihiro Yasoda; Keita P Mori; Haruko Watanabe-Takano; Chiaki Nagai-Okatani; Yui Yamashita; Keisho Hirota; Yohei Ueda; Ichiro Yamauchi; Eri Kondo; Shigeki Yamanaka; Yoriko Sakane; Kazumasa Nakao; Toshihito Fujii; Hideki Yokoi; Naoto Minamino; Masashi Mukoyama; Naoki Mochizuki; Nobuya Inagaki
Journal:  J Clin Invest       Date:  2017-10-09       Impact factor: 14.808

9.  Regulation of the Natriuretic Peptide Receptor 2 (Npr2) by Phosphorylation of Juxtamembrane Serine and Threonine Residues Is Essential for Bifurcation of Sensory Axons.

Authors:  Hannes Schmidt; Deborah M Dickey; Alexandre Dumoulin; Marie Octave; Jerid W Robinson; Ralf Kühn; Robert Feil; Lincoln R Potter; Fritz G Rathjen
Journal:  J Neurosci       Date:  2018-09-24       Impact factor: 6.167

10.  Reduced ability of C-type natriuretic peptide (CNP) to activate natriuretic peptide receptor B (NPR-B) causes dwarfism in lbab -/- mice.

Authors:  Andrea R Yoder; Andrew C Kruse; Cathleen A Earhart; Douglas H Ohlendorf; Lincoln R Potter
Journal:  Peptides       Date:  2008-05-08       Impact factor: 3.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.